If you’re a specialist seeking reliable, cutting-edge oncology medical articles or in-depth haematology medical articles, you’re in the right place. Our blog delivers trusted oncology education content and haematology research updates tailored for dedicated professionals like you. Stay informed with timely oncology news for doctors and breakthrough developments that shape clinical practice. Plus, you can participate in medical studies through our vetted platform, where your insights are valued in exclusive paid research for oncologists and paid research for haematologists.
Welcome to your go-to destination for oncology medical articles and haematology medical articles designed specifically for today’s clinical leaders.
Beyond reading, we invite you to participate in medical studies through our haematology research panel or oncology research surveys—engaging opportunities in physician market research, medical opinion studies, and compensated doctor research. Explore our platform and get involved in paid research for oncologists and paid research for haematologists that values your expertise and insights.
Are you working as an oncologist or haematologist? You can contribute to future oncology developments by sharing your opinions, experience, and medical expertise by participating in healthcare market research with M3.
The number of research projects and trials for oncology drugs conducted per year has nearly quadrupled since 2000, increasing from 421 to 1,489 trials in 2021. Research shows that clinical trials for oncology drugs involve more complexity compared to other drugs, and a very small percentage are brought to market.
In 2021, FDA approved 16 new oncology-related drugs. The average approval process from pre-clinical testing to approval is 12 years for new drugs and seven for devices, with studies revealing that the average development cost ranges from $1.3 – 2.8 billion. In a nutshell, developing new treatments is very time-consuming and expensive, and oncology is one of the most complex and fast-changing therapeutic areas. Extensive research continuously provides new findings that constantly update our understanding and best practices of how to prevent, diagnose, treat, and recover from cancer.
Healthcare market research has a major part in the process of developing new oncology therapies and treatments, as the final stages require market insights from oncologists and patients to understand how the products and devices are being used, perceived, and experienced in real life. These valuable insights provided in market research studies are then used to further develop and adjust new therapies and treatments to improve patient outcomes.
Register today to join our oncology panel and take part in paid market research studies for oncologists.
Once considered peripheral to cancer care, gut microbial ecosystems are now understood to influence immune activation, inflammation, and drug metabolism, all of which are critical to how gut health affects cancer therapy.
Explore tumour imaging, genomics, and federated learning in cancer research to advance precision oncology and personalized cancer treatment.
Traditional cancer biopsies, while effective, often involve invasive procedures that can be difficult for patients. This has sparked a growing interest in liquid biopsy. We explore the benefits, limitations, and future of this cutting-edge approach to cancer screening.
The search for a cancer cure has progressed since the 19th century, yet major challenges remain: cancer heterogeneity, complex tumor environments, asymptomatic cases, metastasis, drug resistance, accessibility, and prevention strategies. Explore these critical areas in the fight against cancer.
New technologies and advancements in hormone therapy, immunotherapy, and targeted therapy are transforming the oncology treatment landscape. Here are some of the important oncology developments and new FDA-approved cancer drugs during 2023.
The pursuit of becoming an oncologist is not an easy one. The journey is long and can be filled with challenges. Read what Dr Gregory Nalesnik has to say in this interview article.